Takeda Wins FDA Approval for First-of-Its-Kind Treatment for Rare Blood Cancer
Synopsis
The FDA has approved Takeda Pharmaceutical and Protagonist Therapeutics’ rusfertide for polycythemia vera, offering patients a less-invasive alternative to frequent bloodletting procedures used to control excessive red blood cell production.
The US Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat polycythemia vera, a rare blood cancer that has traditionally required patients to undergo frequent blood-removal procedures.
“The treatment, rusfertide, will be sold under the brand name Mimrylo and is expected to be available within 48 hours of the FDA’s approval”, said Teresa Bitetti, Takeda’s Global Oncology Chief.
The company has not disclosed its launch price but said it intends to balance the drug’s value with patient access.
Polycythemia vera affects roughly 90,000 people in the United States. The condition causes bone marrow to produce excessive red blood cells which makes the blood thicker and increases the risk of serious complications including blood clots, strokes and heart attacks.
A New Approach to Blood Cancer Treatment
For decades, therapeutic phlebotomy, which involves regularly removing blood from patients, has been a central treatment for managing the disease. Although effective in controlling red blood cell levels, the procedure can be burdensome and uncomfortable for patients who require repeated blood draws.
Mimrylo takes a different approach. It mimics hepcidin, the body’s main iron-regulating hormone, restricting iron availability and reducing the bone marrow’s ability to produce excessive red blood cells.
The FDA based its approval on late-stage clinical trials in which Mimrylo, when added to standard treatment, helped patients maintain control of red blood cell levels. The therapy also reduced the need for blood draws and improved symptoms such as fatigue.
Takeda Targets Billion-Dollar Sales
The approval gives Takeda access to a potentially significant new market in rare blood cancers. The Japanese pharmaceutical company expects Mimrylo to generate $1 billion to $2 billion in peak global annual sales.
Takeda obtained global rights to co-develop and commercialize rusfertide from Protagonist under a licensing agreement signed in 2024.
The approval also strengthens the companies’ position in a disease area where treatment options have historically focused on managing symptoms and reducing the risk of complications rather than addressing the underlying excess production of red blood cells.
For patients, the introduction of Mimrylo could mark a meaningful shift toward a less invasive way of controlling polycythemia vera while Takeda will now face the challenge of making the therapy broadly accessible as it builds a commercial market around the new treatment.
Source: Reuters
Vishal is an experienced Editor at Inspirepreneur Magazine with key interests in artificial intelligence, eCommerce, entrepreneurship, lifestyle and startup sector. Prior to joining Inspirepreneur, he was a Content Writer cum Correspondent at Siliconindia Magazine, where he worked on Company Profiles, Cover Stories, Executive Profiles, Feature Articles and Thought Leadership content.
You Might Also Like
Kalshi targets insider trading risks with new compliance framework
Rising Global Trade Faces Challenges from Geopolitical Tensions
